Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know

Benzinga_recent_news10-31

Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday. Check out the current price of INTS stock here. Shares of the biotechnology company rallied 394.9% in Thursday's regular ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579543969?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/31/Stocks--Bonds--Market.jpeg?optimize=medium&dpr=2&auto=webp&width=120","is_english":true,"pubTime":"2025-10-31 14:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579543969","market":"us","top_or_hot":-1,"title":"Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know","media":"Benzinga_recent_news","content":"<div>\n<p>Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday.\nCheck out the current price of INTS stock here. \nShares of the biotechnology company rallied 394.9% in Thursday's regular ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-31 14:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday.\nCheck out the current price of INTS stock here. \nShares of the biotechnology company rallied 394.9% in Thursday's regular ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know","article_id":"2579543969","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/31/Stocks--Bonds--Market.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48550814/intensity-therapeutics-stock-cools-after-hours-following-395-surge-what-you-should-know","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579543969","pubTimestamp":1761891240,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer therapy INT230-6.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","INTS":"Intensity Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Intensity Therapeutics股价在盘后飙升395%后降温：您应该知道什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INTS":1,"LENZ":1.5},"content_text":"Intensity Therapeutics Inc. (NASDAQ:INTS) shares are trending on Friday.\nCheck out the current price of INTS stock here. \nShares of the biotechnology company rallied 394.9% in Thursday's regular session after Phase 1/2 clinical trial results for INT230‑6, an intratumoral therapy combining cisplatin and vinblastine sulfate, were published in eBioMedicine, but the gains tapered in after-hours trading to $0.90, a 31.9% decline.\nIntensity Therapeutics announced on Thursday that the IT-01 study manuscript, \"Safety and Efficacy of Intratumourally Administered INT230-6 in Adult Patients with Advanced Solid Tumours: Results from an Open-Label Phase 1/2 Dose Escalation Study,\" was published on Wednesday in eBioMedicine, a Lancet Discovery Science journal.\nJacob Stephen Thomas, assistant professor of clinical medicine at USC's Keck School of Medicine and medical oncologist at USC's Norris Comprehensive Cancer Center, served as the study's first author.\nSee Also: Atlassian Stock Pops On Better-Than-Expected Q1 Results Driven By ‘Relentless Pace Of AI Innovation’\nThe trial enrolled 64 heavily pretreated patients with more than 20 advanced cancer types who had progressed after multiple prior therapies. INT230-6 demonstrated a 75% disease control rate and a median overall survival of 11.9 months.\nAccording to an exploratory analysis, patients who received doses of INT230-6 to treat more than 40% of the total tumor burden had an 83.3% disease control rate, while those who received doses for less than 40% had a 50% disease control rate. With a hazard ratio of 0.17, the median overall survival was 18.7 months as opposed to 3.1 months.\nMetastatic sarcoma patients receiving INT230-6 alone achieved median overall survival of 21.3 months.\nNo dose-limiting toxicities were observed in patients receiving monotherapy. Seven patients (10.9%) experienced grade 3 adverse events, with no grade 4 or 5 treatment-related events. \nMore than 95% of the cytotoxic agents that were injected remained in the tumors, according to pharmacokinetic data, which measures drug absorption and distribution in the body.\nThe company has also initiated a Phase 3 sarcoma study.\nLewis H. Bender, Founder, President, and CEO, said the study results “show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy.”\nThe stock of the late-stage clinical company is down 24.5% year to date but has surged 123.9% over the past six months.\nIntensity Therapeutics’ 52-week range is $0.19 to $3.40, with a market capitalization of $64.05 million.\nPrice Action: INTS shares closed Thursday's regular session at $1.32, according to Benzinga Pro data.\nBenzinga Edge Stock Rankings show that INTS is trending downward across all time frames. Here is how the stock fares on other parameters.\nRead Next:\nPhoto: Zakharchuk via Shutterstock\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579543969","isCrawlerRequest":true}